DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight” report provides comprehensive insights about 80+ companies ...

The results of a phase 2b ENLIVEN trial of FGF21 analogue pegozafermin showed it was able to reduce scarring (fibrosis) in the liver of NASH patients at more than three times the rate of a placebo ...

This article reviews evidence that causally links hormonal disorders with hepatobiliary disease, and gives particular focus to nonalcoholic steatohepatitis (NASH). The downstream mechanisms by ...

1). That suggests HepaStem could act on the mechanisms of cirrhosis, fibrosis, and control the acute and sub chronic inflammation that respectively contributes to ACLF and NASH. These are major ...

The results demonstrated a statistically significant fibrosis benefit, which Smith regards as transformational for the field and supportive of ETNB's FGF21 analog, pegozafermin, in NASH.

Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.